Predict your next investment

Corporation
photonamic.de

See what CB Insights has to offer

About photonamic

photonamic engages in developing 5-aminolevulinic acid in the field of fluorescence diagnosis and photodynamic therapy.

photonamic Headquarter Location

Theaterstr. 6

Wedel, 22880,

Germany

49 (0)4103-8006-707

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest photonamic News

photonamic GmbH & Co. KG (Germany) Acquires the Oncology Business from MolecuLight ™ Inc. (Canada)

Sep 11, 2019

Reposted from Moleculight | Photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the Oncology Business of MolecuLight Inc. (Head office: Toronto, Canada; CEO: Anil Amlani) (“MolecuLight”), through its newly formed subsidiary, SBI ALApharma Canada. MolecuLight is a leader in the wound care field with their novel MolecuLight i:X® point-of-care fluorescence imaging device for chronic wounds, which has also undergone successful research in Oncology. Photonamic and MolecuLight have been collaborating for a number of years in the Oncology market, combining MolecuLight´s fluorescence detection technology with photonamic´s 5-ALA agent. MolecuLight´s fluorescent imaging platform for Oncology called “Eagle®” supports surgeons in tumor resection after 5-ALA had been administered to patients. 5-ALA, manufactured by photonamic, is accumulated exclusively in tumor cells and is metabolized to Protoporphorine IX (PP IX) which, under blue light (400 nm), emits pink fluorescence. This fluorescence-guided surgery (FGS) procedure combining both technologies has already been tested in clinical settings for breast cancer surgery by MolecuLight and photonamic in collaboration with University Health Network (UHN), one of the largest healthcare research institutes in North America

photonamic Acquisitions

2 Acquisitions

photonamic acquired 2 companies. Their latest acquisition was MolecuLight - Oncology Business on August 14, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/14/2019

$99M

Acquired Unit

3

4/30/2018

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/14/2019

4/30/2018

Investment Stage

Other

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Sources

3

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.